Last updated: 2026-09-09 19:18:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Harmony Biosciences Holdings, Inc. (HRMY) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $41.53, with a market capitalization of $2.46B and a P/E ratio of 13.52. Over the past 52 weeks, its price has ranged from $25.52 to $43.49. This page covers its latest market performance, valuation, price trends and company information.
$2.46B | |
$41.98 | |
$62.09 | |
$18.61 | |
$42.07 | |
759.65K | |
837.27K | |
13.52 | |
$43.49 | |
$25.52 | |
-- | |
-- |
Harmony Biosciences Holdings, Inc. (HRMY) is currently trading at $41.53 as of 2026-09-09 19:17:00, down 1.28% ($0.54) from the previous close of $42.07
During today's regular trading session, HRMY has traded between $18.61 and $62.09, with a trading volume of 759.65K shares. The current price is near the middle of today's range.
Over the past seven days, Harmony Biosciences Holdings, Inc. (HRMY) moved from $39.21 to $41.53, representing a gain of 5.92% ($2.32).
The stock traded between $38.97 and $43.49 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 964.86 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 89.1%
HRMY is currently trading at $41.53, placing it 89.1% of the way from its 52-week low of $25.52 to its 52-week high of $43.49. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 293 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Harmony Biosciences Holdings, Inc. (HRMY) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.